CatSci Announces Appointment of New Board Members

January 3, 2020

Source: Pharmaceutical Technology's In the Lab eNewsletter

Issue 1,Volume 15

The board consists of industry thought leaders who will work to develop new service offerings for the company.

In an effort to expand its chemistry, manufacturing, and controls capabilities, CatSci, a United Kingdom-based research and development contract research organization (CRO), announced the appointment of members to its new strategic advisory board on Dec. 11, 2019.

The board consists of industry thought leaders who will work to develop new service offerings for the company while improving value for its customer base, increasing its number of small-molecule therapeutics, and creating 500 jobs by 2030, according to a company press release. The board will also introduce two new laboratories to increase capacity at the company.

“We are delighted that CatSci is entering another exciting new phase of its strategic growth plan,” said Dr. Ross Burn, CEO, CatSci, in the press release. “The appointment of this new advisory board is a pivotal step for the company and the new laboratories will enable us to develop more commercially and environmentally sustainable processes for the benefit of patients worldwide. This is an incredibly exciting time to be working at the company, as we continue our journey towards our vision of becoming the preferred partner for process research and development of small-molecule therapeutics.”

The newly appointed board members include:

  • Dr. Andy Jones of MedrusPharma Consulting Ltd, board chair

  • Dr. Andy Wells of Charnwood Technical Consulting Ltd

  • Dr. Mike Rowley of Xelaro Ltd

  • Dr. Nigel Richardson, head of Analytical Technology and Automation at GlaxoSmithKline.

Source: CatSci